|
US5443956A
(en)
|
1985-01-29 |
1995-08-22 |
Oncogene Science, Inc. |
Detection, quantitation and classification of RAS proteins in body fluids and tissues
|
|
GB9103974D0
(en)
|
1991-02-26 |
1991-04-10 |
Norsk Hydro As |
Therapeutically useful peptides or peptide fragments
|
|
US9340577B2
(en)
|
1992-08-07 |
2016-05-17 |
Epimmune Inc. |
HLA binding motifs and peptides and their uses
|
|
BR9708161A
(pt)
|
1996-03-11 |
1999-07-27 |
Epimmune Inc |
Peptídeos com aumentada afinidade de ligação para moléculas hla
|
|
US20020155093A1
(en)
|
1997-02-18 |
2002-10-24 |
Houghton Alan N. |
Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
|
|
EP1085892A4
(en)
|
1998-06-12 |
2002-07-17 |
Sloan Kettering Inst Cancer |
VACCINATION STRATEGY FOR PREVENTING AND TREATING CANCERS
|
|
WO2001036452A2
(en)
|
1999-11-18 |
2001-05-25 |
Epimmune Inc. |
Heteroclitic analogs of class i epitodes
|
|
US6602510B1
(en)
|
2000-04-05 |
2003-08-05 |
Epimmune Inc. |
HLA class I A2 tumor associated antigen peptides and vaccine compositions
|
|
US20030224036A1
(en)
|
1999-12-13 |
2003-12-04 |
Fikes John D |
Hla class I a2 tumor associated antigen peptides and vaccine compositions
|
|
US20070098776A1
(en)
|
1999-12-13 |
2007-05-03 |
Fikes John D |
HLA class I A2 tumor associated antigen peptides and vaccine compositions
|
|
CA2394741A1
(en)
|
1999-12-21 |
2001-06-28 |
Epimmune Inc. |
Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
|
|
FR2812087B1
(fr)
|
2000-07-21 |
2007-05-11 |
Inst Nat Sante Rech Med |
Procede de criblage de peptides utilisables en immunotherapie
|
|
US20020164346A1
(en)
|
2001-02-14 |
2002-11-07 |
Nicolette Charles A. |
Altered peptide ligands
|
|
WO2003008537A2
(en)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
EP1495322A4
(en)
|
2002-04-05 |
2006-09-06 |
Epimmune Inc |
HETEROKLITIC ANALOGUES AND ASSOCIATED METHODS
|
|
CA2500687A1
(en)
|
2002-10-02 |
2004-04-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
WO2005012502A2
(en)
|
2003-03-28 |
2005-02-10 |
Idm Pharma, Inc. |
Methods of identifying optimal variants of peptide epitopes
|
|
ES2456666T3
(es)
|
2003-04-18 |
2014-04-23 |
Biotech Synergy, Inc. |
Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
|
|
WO2005042698A2
(en)
|
2003-10-23 |
2005-05-12 |
Pecos Labs, Inc. |
T cell epitopes useful in a hepatitis c virus vaccine and as diagnostic tools and methods for identifying same
|
|
EP2478913A1
(en)
|
2003-12-01 |
2012-07-25 |
Sloan-Kettering Institute For Cancer Research |
Synthetic HLA binding peptide analogues and uses thereof
|
|
CA2566506A1
(en)
|
2004-06-01 |
2005-12-15 |
Innogenetics N.V. |
Peptides for inducing a ctl and/or htl response to hepatitis c virus
|
|
DE602006006046D1
(de)
|
2005-05-09 |
2009-05-14 |
Vaxon Biotech |
Verwendung nativer peptide und deren optimierter derivate zur impfung
|
|
WO2006124408A2
(en)
|
2005-05-12 |
2006-11-23 |
Merck & Co., Inc. |
System and method for automated selection of t-cell epitopes
|
|
AU2006259307B2
(en)
|
2005-06-17 |
2012-12-20 |
Mannkind Corporation |
Epitope analogues
|
|
CA2626238C
(en)
|
2005-10-17 |
2015-10-06 |
Memorial Sloan Kettering Cancer Center |
Wt1 hla class ii-binding peptides and compositions and methods comprising same
|
|
WO2007073768A1
(en)
|
2005-12-23 |
2007-07-05 |
Vaxon Biotech |
Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof
|
|
WO2008010010A1
(en)
|
2006-07-12 |
2008-01-24 |
Vaxon Biotech |
Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
|
|
WO2009002418A2
(en)
|
2007-06-21 |
2008-12-31 |
Merck & Co., Inc. |
T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
|
|
EP2215111B1
(en)
|
2007-11-01 |
2016-03-16 |
Mayo Foundation For Medical Education And Research |
Hla-dr binding peptides and their uses
|
|
EP2324057B1
(en)
|
2008-08-12 |
2018-03-21 |
MSD Italia S.r.l. |
Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
|
|
RS53782B1
(sr)
|
2008-10-01 |
2015-06-30 |
Immatics Biotechnologies Gmbh |
Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
|
|
CN102387813B
(zh)
|
2009-04-02 |
2018-07-31 |
瓦克松生物技术公司 |
用于免疫治疗的隐蔽hla-a24表位的鉴定、优化和用途
|
|
ES2533228T3
(es)
|
2009-06-09 |
2015-04-08 |
Vaxon Biotech |
Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia
|
|
GB201006360D0
(en)
|
2010-04-16 |
2010-06-02 |
Immatics Biotechnologies Gmbh |
Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
|
|
WO2011149909A2
(en)
|
2010-05-24 |
2011-12-01 |
Hunt Donald F |
Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
|
|
PL3892295T3
(pl)
|
2011-05-24 |
2023-07-24 |
BioNTech SE |
Zindywidualizowane szczepionki przeciwnowotworowe
|
|
BR112015025460B1
(pt)
|
2013-04-07 |
2024-01-02 |
The Broad Institute, Inc. |
Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
PT3079715T
(pt)
|
2013-12-09 |
2018-08-02 |
Targovax Asa |
Uma mistura de péptidos
|
|
US10238741B2
(en)
|
2014-10-10 |
2019-03-26 |
The Trustees Of Columbia University In The City Of New York |
Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
|
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
RU2719033C2
(ru)
|
2015-04-23 |
2020-04-16 |
Нантомикс, Ллс |
Способ получения фармацевтического агента для иммунотерапии рака
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
CA2986235A1
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
CR20180519A
(es)
|
2016-03-31 |
2019-03-05 |
Neon Therapeutics Inc |
Neoantígenos y métodos de su uso
|
|
US11296398B2
(en)
|
2016-10-06 |
2022-04-05 |
Avery Dennison Retail Information Services Llc |
Methods for creating RFID tags based on flexible antenna materials
|
|
EP4714454A2
(en)
|
2016-10-26 |
2026-03-25 |
Acuitas Therapeutics Inc. |
Lipid nanoparticle formulations
|
|
TWI728201B
(zh)
|
2016-11-01 |
2021-05-21 |
丹麥商諾佛 儂迪克股份有限公司 |
耐受性ｄｎａ疫苗
|
|
WO2018094569A1
(zh)
|
2016-11-22 |
2018-05-31 |
深圳华大基因研究院 |
多肽及其应用
|
|
CA3035591A1
(en)
*
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
|
|
WO2018102585A1
(en)
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
|
|
EP3576780A1
(en)
|
2017-02-01 |
2019-12-11 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
CN116693695A
(zh)
|
2017-02-12 |
2023-09-05 |
百欧恩泰美国公司 |
基于hla的方法和组合物及其用途
|
|
EP3592381A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
JP7457642B2
(ja)
|
2017-04-03 |
2024-03-28 |
ビオンテック ユーエス インコーポレイテッド |
タンパク質抗原およびその使用
|
|
WO2018188730A1
(en)
|
2017-04-11 |
2018-10-18 |
Biontech Rna Pharmaceuticals Gmbh |
Rna for treatment of autoimmune diseases
|
|
EP3400959A1
(en)
|
2017-05-09 |
2018-11-14 |
Vaxon Biotech |
Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a hla-a*0201-positive patient having a non-immunogenic tumor expressing tert
|
|
CN111655714A
(zh)
|
2017-11-08 |
2020-09-11 |
阿德瓦希斯公司 |
来自癌症相关蛋白的免疫原性异变肽及其使用方法
|
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
|
TW202000907A
(zh)
|
2018-05-23 |
2020-01-01 |
美商葛利史東腫瘤科技公司 |
共有抗原
|
|
WO2019246286A1
(en)
|
2018-06-19 |
2019-12-26 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
|
TW202513579A
(zh)
|
2018-06-19 |
2025-04-01 |
美商百歐恩泰美國公司 |
新抗原及其用途
|
|
SG11202012770RA
(en)
|
2018-06-27 |
2021-01-28 |
Modernatx Inc |
Personalized cancer vaccine epitope selection
|
|
WO2020020444A1
(en)
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
WO2020037239A1
(en)
|
2018-08-16 |
2020-02-20 |
Neon Therapeutics, Inc. |
T cell receptor constructs and uses thereof
|
|
US20200069782A1
(en)
|
2018-08-28 |
2020-03-05 |
CeCaVa GmbH & Co. KG |
Methods for selecting tumor-specific neoantigens
|
|
CA3127673A1
(en)
|
2019-01-25 |
2020-07-30 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting mutant ras
|
|
WO2020252039A1
(en)
|
2019-06-12 |
2020-12-17 |
Biontech Us Inc. |
Neoantigen compositions and uses thereof
|
|
CN112110995A
(zh)
|
2019-06-19 |
2020-12-22 |
上海交通大学医学院 |
肿瘤新抗原多肽及其用途
|
|
WO2021055594A1
(en)
*
|
2019-09-20 |
2021-03-25 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
WO2021087840A1
(zh)
|
2019-11-07 |
2021-05-14 |
武汉华大吉诺因生物科技有限公司 |
肿瘤免疫治疗多肽及其应用
|
|
WO2021101965A1
(en)
|
2019-11-18 |
2021-05-27 |
Epivax Oncology, Inc. |
Improved neo-epitope vaccines and methods of treating cancer
|
|
US11977057B2
(en)
|
2020-06-13 |
2024-05-07 |
Complete Omics International Inc. |
Method and system for neoantigen analysis
|
|
WO2022036142A2
(en)
|
2020-08-13 |
2022-02-17 |
Biontech Us Inc. |
Ras neoantigens and uses thereof
|
|
US11058751B1
(en)
*
|
2020-11-20 |
2021-07-13 |
Think Therapeutics, Inc. |
Compositions for optimized RAS peptide vaccines
|
|
US11161892B1
(en)
|
2020-12-07 |
2021-11-02 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
CA3202176A1
(en)
|
2020-12-14 |
2022-06-23 |
Michael Steven ROONEY |
Tissue-specific antigens for cancer immunotherapy
|
|
US12275766B2
(en)
*
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
EP4293043A4
(en)
|
2021-02-10 |
2025-09-10 |
Shanghai Genbase Biotechnology Co Ltd |
EPITOPE PEPTIDE OF THE RAS G13D MUTANT AND T LYMPHOCYTE RECEPTOR RECOGNIZING THE RAS G13D MUTANT
|
|
WO2022180219A1
(en)
|
2021-02-25 |
2022-09-01 |
Kosmatopoulos Kostantinos Kostas |
Optimized vaccine to elicit a t cell immunity against sars-cov-2
|
|
US11464842B1
(en)
*
|
2021-04-28 |
2022-10-11 |
Think Therapeutics, Inc. |
Compositions and method for optimized peptide vaccines using residue optimization
|
|
WO2023170535A2
(en)
|
2022-03-04 |
2023-09-14 |
Proof Diagnostics, Inc. |
Novel nucleic acid-guided nucleases and use thereof
|
|
CA3250649A1
(en)
|
2022-05-23 |
2023-11-30 |
Fred Hutchinson Cancer Center |
Binding proteins and specific modified cells of neoantigens and their uses
|